Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1794
  • Dowloads 148

Original Research

Open Access

Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer

  • H. Nomura1
  • H. Tsuda1,*,
  • F. Kataoka1
  • T. Chiyoda1
  • W. Yamagami1
  • E. Tominaga1
  • N. Susumu1
  • D. Aoki1

1Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan

DOI: 10.12892/ejgo20120186 Vol.33,Issue 1,January 2012 pp.86-89

Published: 10 January 2012

*Corresponding Author(s): H. Tsuda E-mail: htsud@sc.itc.keio.ac.jp

PDF (105.86 kB) View Full-text

Abstract

Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m(2)) was administered intravenously on days I, 8 and 15 every four weeks. PLD (50 mg/m2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05). respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-II group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.

Keywords

Ovarian cancer; Recurrence; Platinum-resistant; Irinotecan; Liposomal doxorubicin

Cite and Share

H. Nomura, H. Tsuda, F. Kataoka, T. Chiyoda, W. Yamagami, E. Tominaga, N. Susumu, D. Aoki. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2012; 33(1): 86-89. doi: 10.12892/ejgo20120186

URL:

https://www.ejgo.net/articles/10.12892/ejgo20120186

References

[1] Japan Society of Gynecologic Oncology. Ovarian Cancer Treatment Guidelines 2007. Tokyo, Japan, Kanehara & Co., Ltd; 2007.

[2] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[3] The National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 2. 2010). Database online, 2010.

[4] Matsumoto K., Katsumata N., Yamanaka Y., Yonemori K., Kohno T., Shimizu C et al.: “The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer”. Gynecol. Oncol., 2006, 100, 412.

[5] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A. et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[6] Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: “Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan”. J Clin Oncol. 2001, 19, 3312.

[7] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D. et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[8] ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I. et al.: “Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer”. J. Clin. Oncol., 1997, 15, 2183.

Submission Turnaround Time

Top